| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $300K | — |
| Cost of Revenue | $200K | — |
| R&D Expense | $493.9M | +38.1% |
| Operating Income | -$729.3M | -43.1% |
| Pre-tax Income | -$617.9M | -15.2% |
| Income Tax | $300K | +50.0% |
| Net Income | -$618.2M | -15.2% |
| EPS (Basic) | -$0.99 | +30.3% |
| EPS (Diluted) | -$0.99 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.02B | +22.4% |
| Current Assets | $2.08B | +141.9% |
| Total Assets | $2.47B | +146.3% |
| Current Liabilities | $104.4M | +46.8% |
| Long-term Debt | $80.3M | +25.5% |
| Total Liabilities | $263.1M | +5.8% |
| Stockholders' Equity | $2.20B | +192.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$432.9M | -17.4% |
| Capital Expenditures | $78.8M | -3.9% |
| Investing Cash Flow | -$1.18B | -1334.1% |
| Financing Cash Flow | $1.80B | +119.0% |
| Free Cash Flow | -$511.7M | -13.6% |
| +30.3% |